Memantine hydrochloride

Product Description

Memantine hydrochloride is an antagonist at the NMDA receptor (IC₅₀ = 0.5 -1.5 μM in vitro), binding to the ion channel site. Memantine increases BDNF protein and mRNA levels in the brain in vivo. In an animal model of Alzheimer's disease, memantine improves spatial learning and decreases deposition of Aβ plaques. Memantine has neuroprotective effects in dopaminergic neurons; stimulates release of neurotrophic factor from astroglia and reduces microglia inflammation in vitro.

Solubility

Preparing Stock Solutions for Memantine hydrochloride

The following data is based on the product molecular weight 215.77

Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which all affect the solvent volumes required to prepare stock solutions.

Select a batch to recalculate based on the batch molecular weight:

10 9 8 7 6 5 4 3 Recalculate

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	4.63 mL	23.17 mL	46.35 mL
5 mM	0.93 mL	4.63 mL	9.27 mL
10 mM	0.46 mL	2.32 mL	4.63 mL
50 mM	0.09 mL	0.46 mL	0.93 mL

Calculators

Background References

References are publications that support the biological activity of the product.

• Dong Effects of memantine on neuronal structure and conditioned fear in the Tg2576 mouse model of Alzheimer's disease. Neuropsychopharmacology 2008 PMID: 18418360
• Minkeviciene Memantine improves spatial learning in a transgenic mouse model of Alzheimer's disease. J.Pharmacol.Exp.Ther. 2004 PMID: 15192085
• Wu Novel neuroprotective mechanisms of memantine: increase in neurotrophic factor release from astroglia and anti-inflammation by preventing microglial activation. Neuropsychopharmacology 2009 PMID: 19536110
• Zajaczkowski Uncompetitive NMDA receptor antagonists attenuate NMDA-induced impairment of passive avoidance learning and LTP. Neuropharmacology 1997 PMID: 9257940
• Parsons Mem.: A NMDA receptor antagonist that improves memory by restoration of homeostasis in the glutamatergic system - too little activation is bad, too much is even worse. Neuropharmacology 2007 PMID: 17904591
• Parsons Mem. is a clinically well tolerated N-MthD.-aspartate (NMDA) receptor antagonist - a review of preclinical data. Neuropharmacology 1999 PMID: 10465680
• Chen Neuroprotective concentrations of the N-MthD.-aspartate open-channel blocker Mem. are effective without cytoplasmic vacuolation following post-ischemic administration and do not block maze learning or long-term potentiation. Neuroscience 1998 PMID: 9697119